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Abstract
Background—Children with cancer experience multiple symptoms due to their disease and as a 
result of treatment. The purpose of this study was to demonstrate the feasibility and potential 
utility of using latent profile analysis (LPA), a type of cluster analysis, in children with cancer to 
identify groups of patients who experience similar levels of symptom severity and impairment of 
physical function.
Procedure—We analyzed patient-reported symptom and functional data previously collected 
using the Pediatric Patient Reported Outcomes Measurement Information System (PROMIS). 
LPA was used to identify and characterize groups of patients who reported similar levels of 
symptom severity and functional impairment. We then used the multinomial logit model to 
examine demographic and disease characteristics associated with symptom/ function profile 
membership.
Results—The analysis included 200 patients in treatment or in survivorship. We identified four 
symptom/ function profiles; children currently receiving cancer treatment and those with at least 
one other medical problem were more likely to be members of the profile with the highest levels 
of symptom severity and functional impairment. Gender, age, race/ethnicity, and tumor type were 
not associated with profile membership.
Conclusions—LPA is a cluster research methodology that provides clinically useful results in 
pediatric oncology patients. Future studies of children with cancer using LPA could potentially 
lead to development of clinical scoring systems that predict patients’ risk of developing more 
severe symptoms and functional impairments, allowing clinicians, patients, and parents to better 
anticipate and prevent the multiple symptoms that occur during and after treatment for childhood 
cancer.
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INTRODUCTION
More than 12,000 children in the United States will be diagnosed with cancer in 2014, and 
nearly all of them will experience multiple symptoms and functional impairments as a result 
of their disease and its treatment [1,2]. As we increase awareness of how these negative 
experiences impact children's well-being, efforts to better understand, prevent, and manage 
the adverse effects of cancer therapies emerge. Use of patient-reported measures of 
symptoms and function enhances more traditional outcome data collected in clinical studies 
of cancer therapy by describing each patient's personal experience with his or her illness 
[3,4]. Interpreting this valuable information can be challenging, because children with 
cancer experience varying degrees of symptom and functional impairments, both of which 
can occur alone or concurrently [5]. In this study, we applied latent profile analysis (LPA) to 
identify groups of children who experienced similar and dissimilar levels or patterns of co-
occurring symptoms and functional impairments [6]. Using LPA to recognize which 
children are likely to experience these patterns of symptoms and functional impairments 
may help clinicians anticipate and mediate their effects on the children's quality of life.
The study of multiple symptoms, collectively termed symptom cluster research, has been 
used by several scientific disciplines to identify co-occurring events, behaviors, or 
psychological phenomena [7]. These techniques were first applied in the field of cancer 
outcomes research a little over a decade ago, in an effort to identify associations among 
symptoms experienced during cancer treatment and expand our understanding of the 
mechanisms underlying symptom development [8]. Researchers in this relatively nascent 
area of investigation have yet to reach consensus on the ideal methodology(ies) to use for 
the purposes of informing clinical oncology practice [9]. Most studies have utilized 
statistical approaches such as simple correlation, principal component analysis, common 
factor analysis, or cluster analysis to identify symptom groupings or clusters, such as 
nausea-vomiting, pain-insomnia-fatigue, and fatigue-depression [10–12]. Only a few of 
these investigations have involved reports from children with cancer [13–17].
LPA has not previously been used to study children with cancer, and it differs from other 
statistical approaches used in symptom cluster research in several important ways. LPA, one 
of the mixture models, is a model-based approach used to group patients into distinctive 
profiles. Unlike the traditional cluster analysis that uses ad hoc dissimilarity measures, such 
as Euclidean distance, to identify clusters, LPA identifies groups based on probability. In 
addition, LPA provides statistical tests and indices for model goodness-of-fit assessment 
[18,19]. Unlike factor analysis that identifies groups of variables measuring symptoms, LPA 
categorizes patients into groups based on their responses to the items measuring symptom 
severity. The goal of grouping patients into these latent profiles is to identify shared 
underlying characteristics that might contribute to the likelihood of membership within a 
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particular latent profile [10,20,21]. For example, patients who receive a particular treatment 
regimen may be more likely to be members of a latent profile that experiences higher levels 
of symptom severity than those who receive a different treatment regimen. One potential 
application of these findings is the development of risk prediction tools that could be used to 
identify patients at the outset of cancer treatment who are more likely to become members of 
a particular symptom profile; foreknowledge of this risk could then be used to modify 
strategies designed to mitigate or prevent future symptoms. For instance, patients predicted 
to be at particular risk for developing higher levels of pain, depression, and anxiety might 
benefit from establishing a relationship with a mental health professional before these 
symptoms develop.
The clinical utility of symptom cluster research in pediatric oncology remains unclear [22]. 
The primary goal of this study is to demonstrate the feasibility and potential utility of LPA 
in pediatric cancer research. We also aim to demonstrate a new method for integrating 
measures of function into the study of patient-reported outcomes in pediatric cancer. The 
rationale for this approach is that our understanding of the impact of cancer and its treatment 
would be enriched by including both symptoms and function in analyses, because both types 
of outcomes help to define a patient's illness experience. Patient clustering based on 
symptoms and functional impairment has not previously been examined in the pediatric 
oncology population [23]. Providing a better understanding of the patient's responses to 
disease and treatments may produce a more clinically useful model, one that could 
potentially be applied directly to patients in the pediatric oncology clinic. The findings of 
this study will inform future efforts to apply symptom cluster research methodology in 
clinical pediatric oncology research, with the ultimate goal of improving our ability to care 
for children with cancer.
METHODS
Participants and Data Collection
The data used in this analysis were collected as part of the Patient-Reported Outcomes 
Measurement Information System® (PROMIS®) pediatric initiative, which has been 
previously described [24]. Children with cancer between the ages of 8 and 17 years from 5 
participating institutions provided information either while receiving treatment for cancer or 
after completing therapy (i.e., on-therapy or in survivorship). A total of 203 pediatric 
oncology patients enrolled in the study; 3 patients did not complete any PROMIS pediatric 
items and are therefore not included in the analysis. Patients were considered to be currently 
receiving cancer treatment if they had received disease-directed therapy within the previous 
45 days. Participants’ guardians completed questions related to patient demographics and 
other health problems, and each guardian was asked to provide his or her highest achieved 
educational level.
Measures
We included four PROMIS symptom domains (anxiety, depression, fatigue, and pain 
interference) and three functional domains (peer relationships, physical functioning-upper 
extremity, and physical functioning-mobility) in this analysis. Scores on the PROMIS 
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measures are on a T-score metric, normed to have a mean of 50 and a standard deviation of 
10 in the original Pediatric PROMIS patient sample [24–28]. Higher scores in the symptom 
domains represent greater symptom burden; in contrast, higher scores in the functional 
domains represent better functioning.
Statistical Analyses
We used LPA [29–34], a posterior membership probability model, to identify subgroups 
(profiles) of patients comprised of individuals with similar levels of symptom severity and 
functional impairment. The optimal number of profiles was determined by generating a 
series of LPA models with an increasing number of latent profiles and iteratively comparing 
each successive model k with the previous (k − 1) model using Akaike, Bayesian, and 
sample-size adjusted Bayesian information criterion indices (AIC, BIC, and SABIC), the 
Lo-Mendell-Rubin likelihood ratio (LMR LR) test [35], the adjusted LMR LR (ALMR LR) 
test, and the bootstrap likelihood ratio test (BLRT) [31,36].
We classified patients into their most likely latent profiles using the estimated posterior 
membership probabilities for each observation. The quality of membership classification 
was assessed by examining average posterior probabilities and the entropy statistic. Next, 
the prevalence rates (i.e., unconditional probabilities) of the latent profiles and the mean 
scores of the PROMIS measures in each latent profile were assessed. Finally, the 
relationships of the latent profile membership with treatment status, as well as individual 
patient characteristics (sex, age, race/ ethnicity, other health problems, guardian's highest 
education, and cancer type) were tested using a multinomial logit model, in which profile 4 
was treated as the reference group. The statistical package Mplus [37] was used for 
modeling.
RESULTS
Demographics and clinical characteristics of the patient sample were described previously 
and are summarized in Table I [24]. Most patients had acute leukemia or lymphoma (n = 
120, 60.0%); the remainder were diagnosed with solid tumors (n = 58, 29.0%) or brain 
tumors (n = 22, 11.0%). The patient sample was racially diverse, with 101 patients (50.5%) 
reporting non-white race. The means and standard deviations of the seven PROMIS 
pediatric outcome measures are shown in Table II. Mean domain scores range from 47.2 to 
48.9, indicating that, on average, our cancer patients are relatively similar to the reference 
group used during development of the pediatric PROMIS measures.
Comparison of LPA models with information criterion indices and likelihood ratio tests 
indicate that the data best fit either a four-or five-profile model, as the BIC, LMR LR, and 
ALMR LR favored four profiles and the AIC, ABIC, and BLRT favored five profiles (Table 
III). We selected the four-profile model for further analysis because it provided better profile 
membership classification and the most useful and interpretable information from a clinical 
perspective. Posterior assignment probabilities for Profiles 1, 2, 3, and 4 were 0.92, 0.91, 
0.91, and 0.97, respectively (i.e., the diagonal figures in Table IV), which are much higher 
than the standard cutoff point of 0.70 [38]. In addition, the entropy statistic of 0.88 was also 
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large, indicating good membership classification [39]. Profile 1 contained 16% of the total 
number of patients; profile 2, 24%; profile 3, 16%; and profile 4, 45%.
Each profile's estimated mean symptom and functioning scores are shown in Figure 1. The 
values of the PROMIS pediatric outcome measures for each profile were distinctive and 
showed clear patterns across the latent profiles. Patients in profile 1 had on average higher 
symptom severity and lower functioning than patients in any other profile. Conversely, 
patients in profile 4 had on average lower symptom severity and better functioning than 
patients in other profiles. Domain scores for profiles 2 and 3 fell between profiles 1 and 4 
and presented a mixed picture: more severe symptoms but better functioning in profile 2, 
and less severe symptoms but worse functioning in profile 3.
Treatment status was the strongest predictor of profile membership (and therefore symptom 
burden and functioning) identified by our analysis (Table V). Children currently receiving 
treatment for cancer had higher symptom severity and poorer functioning compared to those 
who had already completed therapy, as indicated by their having larger odds of being in 
profiles 1, 2, or 3 compared to profile 4 (OR = 6.5 (95% CI: 2.4–17.3), 2.5 (1.1–5.6), and 7.1 
(2.6–19.4), respectively). Likewise, children identified as having at least one other health 
problem in addition to cancer had higher symptom severity and worse functioning than 
children with no additional health problems. The corresponding odds ratios and 95% 
confidence intervals for membership in profiles 1, 2, and 3 were OR = 6.1 (2.3–16.0), 2.4 
(1.1–5.6), and 3.6 (1.3–9.7), respectively. Gender, age, race/ethnicity, guardian education, 
and tumor type were not statistically significant predictors of profile membership.
DISCUSSION
Patient-reported outcomes (PROs) play an important role in helping us understand the 
impact of cancer and its treatments on patients’ lives. Our findings suggest that among 
children with a variety of cancers, there are subgroups of patients who have distinct 
symptom- and function-related phenotypes. Patients actively receiving cancer treatment and 
those who have co-morbid health conditions were more likely to be classified in profiles 
with more severe symptoms and worse functioning than those who have completed therapy 
and have no additional health problems. These results are consistent with our clinical 
expectations and speak to the validity of LPA to summarize patterns of symptom burden and 
functional impairment in this population. The lack of correlation between profile 
membership and demographic characteristics of patients underscores the difficulty of 
predicting symptoms and functional impairments based solely on age, sex, and race/
ethnicity. In addition, the excellent latent profile membership classification by the model 
provides confirmation that the continuous variables produced by the pediatric PROMIS 
measures are suitable for use in LPA modeling.
Direct head-to-head comparison of the different statistical approaches used in symptom 
cluster research has not yet been performed. Such studies would inform future efforts to 
analyze symptom data by allowing researchers to select analytic strategies that yield the 
most clinically useful and interpretable information. Prospective evaluation of multiple 
symptom models to determine which approach is most predictive of change over time would 
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also be informative. These investigations would potentially improve our ability to match 
data analysis methods with the goals of future studies.
The majority of studies of multiple symptoms in cancer patients focus on identifying groups 
of symptoms rather than groups of patients with similar symptom experience phenotypes. 
LPA, a technique for grouping patients in this way, has not previously been applied to PRO 
data in the pediatric cancer population [10]. As shown by our study, LPA can identify 
different patient phenotypes based on symptom severity and functional impairment. This 
approach yields results that are more specific to the experiences of individual patients, as 
compared to an analysis that produces findings at the level of symptoms for the total group. 
Identification and characterization of PRO profiles provide important insight into the 
realities faced by individual patients, a critical first step toward developing tools to predict 
and manage symptoms and functional impairments more effectively.
The concept of grouping patients into different symptom experience phenotypes was 
previously demonstrated by two studies in adults with cancer [40,41]. Both studies 
investigated the “sickness behavior” symptom cluster of pain, fatigue, sleep disturbance, and 
depression in adult outpatients with cancer diagnoses. The investigators used statistical 
techniques similar to those employed by our study to identify distinct groups of patients, 
each with a different profile of symptom severity. Notably, the proportions of patients who 
fell into the “all high severity” and “all low severity” groups in these studies were similar to 
the proportions of patients in our study in Profiles 1 (all high severity) and 4 (all low 
severity).
In contrast to our study, most cluster research studies in pediatric and adult oncology do not 
include measures of function in their analyses [5,9]. Including both symptoms and 
functional outcomes when assessing patients’ responses to illness is essential to our 
understanding how cancer affects patient quality of life. Previous studies have demonstrated 
that functional status not only affects quality of life directly, but also partially mediates the 
effects of symptoms on quality of life [42]. These complex interactions cannot be fully 
appreciated and studied using cluster research methods that do not include measures of 
function as outcomes.
The discordance between symptom severity and functional status seen in profiles 2 and 3 in 
our study highlights the potential utility of including measures of function in LPA profiles. 
This unexpected result raises several interesting questions about what unmeasured factors 
might contribute to the likelihood of membership in these profiles, and it suggests that the 
interactions among symptoms and functional status are more complex than we would 
otherwise appreciate had function not been included in our analysis. In contrast to our study, 
the adult cancer studies described above evaluated the impact of symptom profile 
membership on physical function, rather than including measures of function in the profiles. 
The studies found that the groups of patients who experienced higher levels of symptoms 
had significantly lower functional status, as measured by the Karnofsky Performance Score 
[40,41]. This finding was expected, and it aligns with the levels of symptom severity and 
function observed in profiles 1 and 4 in our study (Fig. 1). Profiles 2 and 3, however, 
revealed the unexpected finding that symptom severity and functional outcomes may not be 
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inextricably linked—a finding that needs to be confirmed and explored by additional 
investigations in this population. In this way, our study demonstrates that including both 
symptoms and functional outcomes in cluster analysis provides a better picture of the impact 
of cancer and its treatment on children's well-being.
The results of our study suggest that it may be possible to use LPA to create a useful tool for 
clinical pediatric oncology practice. Identification of symptom/function profiles and the 
factors associated with profile membership could be used to develop a clinical prediction 
score that prospectively evaluates a patient's risk for developing varying degrees of 
symptom severity and functional impairment during the course of cancer treatment and 
follow up. Making the patterns identified through LPA available to clinicians would 
potentially improve their ability to provide more tailored information for families to help 
them to better anticipate how their child could respond to the cancer treatment experience. 
Foreknowledge of this risk might allow clinicians to modify strategies aimed at preventing 
or mitigating negative outcomes. This is an important goal, as the link between a child's 
symptom experience during cancer treatment and his or her quality of life is clear [43,44]. 
Factors that influence health-related quality of life during cancer treatment may also have an 
impact on childhood development; studying how symptom and functional profiles change 
over time and how they differ by age of the patient might also shed light on how cancer 
treatment affects long-term outcomes and late effects of therapy.
In addition to developing predictive models of profile membership, LPA can also be used to 
investigate biologic mechanisms that underlie specific groups of symptoms. Given the 
observed lack of correlation between symptom profiles and most demographic, disease, and 
treatment-related factors seen in previous studies, investigators hypothesized that there may 
be genetic variations contributing to patients’ experiences with cancer [40,41]. This 
observation led to a study of adult oncology patients that used LPA to identify subgroups of 
patients with different severities of the “sickness behavior” symptom cluster (as described 
above) [45]. The identified subgroups were then correlated with polymorphisms in candidate 
genes believed to contribute to the symptoms of the sickness behavior cluster. The 
investigators identified a single nucleotide polymorphism in the interleukin-4 gene that was 
associated with high levels of all four symptoms, suggesting a possible link between this 
variant of IL-4 and an individual's susceptibility to experiencing more severe symptoms 
during cancer treatment [45]. Others have previously proposed such a connection, but this 
finding awaits further confirmation [46].
Our study raises important questions that are not answered by our analysis due to several 
limitations. The low number of patients with specific cancer types (most notably brain 
tumor) prevented us from determining whether the patient profiles were invariable across 
individual disease types. The odds ratios provided by our model would likely have been 
more precise (i.e., more narrow confidence intervals) with a larger number of patients. 
Limited clinical data were available in our study, making it impossible to examine in more 
detail patient and disease characteristics that might affect profile membership. In addition, 
the setting and timing of the patient assessments were not standardized, so the effects of 
these differences in questionnaire administration on profile membership are not known. 
Finally, the measures used in this analysis were collected at a single point in time for each 
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participant, so we were unable to evaluate how profile characteristics might change over 
time. For example, we cannot determine whether levels of symptom severity and functional 
impairment change during periods of more intensive versus less intensive treatment, and we 
do not know whether patients shift from one profile to another during the course of 
treatment and survivorship. Longitudinal studies of symptoms and functional impairments 
using latent transition analysis, a technique similar to LPA, would provide insight into 
whether the observed profiles persist over time [47,48].
The ultimate aim of this field of research is to improve the well-being of patients with 
cancer through better prevention, recognition, and management of patients’ symptoms and 
functional impairments. The results of our study suggest that future investigations using 
LPA could be used to generate useful clinical tools, such as a clinical prediction score, 
complementing the work already underway using LPA to identify genetic variations that 
affect patients’ experiences with cancer. In these ways, LPA research offers many new 
opportunities to better understand the experience of being treated for cancer as a child. The 
conclusions drawn from this exploratory study of secondary data should not necessarily be 
accepted at face value, but they should be viewed as strong evidence of the potential utility 
of this type of analysis. Future studies of PROs in pediatric cancer patients should include 
detailed plans to evaluate a broader set of symptoms, functional status, and overall quality of 
life domains, so that we can glean as much knowledge as possible from these efforts to 
improve the care of children with cancer.
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Mean PROMIS domain scores of four latent profiles generated by LPA for 200 children 
with cancer. Domain scores are on a T-score metric, normed in the general pediatric 
population to have a mean of 50 and a standard deviation of 10. PROMIS, Patient Reported 
Outcomes Measurement Information System; LPA, latent profile analysis.
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TABLE I
Clinical and Demographic Characteristics of the Pediatric PROMIS Patient Sample
Characteristics No. participants (%; n = 200)
Sex
    Male 111 (55.5)
    Female 89 (44.5)
Age
    8-12 years 91 (45.5)
    13-17 years 109 (54.5)
    Age (mean, SD) 12.9 (2.9)
Race/ethnicity
    Non-Hispanic white 99 (49.5)
    Black or African American 41 (20.5)
    Hispanic 40 (20.0)
    Others 20 (10.0)
Parent/Caregiver's education level
    ≤8th grade 4 (2.0)
    Some high school 5 (2.5)
    High school degree/GED 42 (21.0)
    Some college/technical degree 74 (37.0)
    College degree 49 (24.5)
    Advanced degree 26 (13.0)
History of other health problems
    No other health problems 132 (66.0)
    Yes = 1 other health problem 39 (19.5)
    Yes ≥ 2 other health problems 29 (14.5)
Type of cancer
    Leukemia/lymphoma 120 (60.0)
    Brain tumor 22 (11.0)
    Solid tumor 58 (29.0)
PROMIS, Patient Reported Outcomes Measurement Information System; SD, standard deviation; GED, General Equivalency Diploma.













Buckner et al. Page 14
TABLE II







Pain interference 47.2 (11.3)
Peer relationships 48.9 (10.4)
Physical functioning-upper extremity 48.8 (8.7)
Physical functioning-mobility 47.0 (10.2)
PROMIS, Patient Reported Outcomes Measurement Information System.
*
Sample size slightly varies by measures due to missing values.
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TABLE III
Comparisons of Different LPA Models Using Information Criterion Indices and Likelihood Ratio Tests
P-Value
Model AIC BIC ABIC LMR LR ALMR LR BLRT
1-Profile LCA 10,294.38 10,340.56 10,296.20 — — —
2-Profile LCA 9,859.745 9,932.308 9,862.610 <0.0001 <0.0001 <0.0001
3-Profile LCA 9,793.360 9,892.309 9,797.266 0.0296 0.0318 <0.0001
4-Profile LCA 9,723.661 9,848.997 9,728.609 0.0148 0.0164 <0.0001
5-Profile LCA 9,709.378 9,861.101 9,715.368 0.2057 0.2153 <0.0001
Not applicable. LPA, latent profile analysis; AIC, Akaike information criterion; BIC, Bayesian information criterion; ABIC, sample-size adjusted 
Bayesian information criterion; LMR LR, Lo-Mendell-Rubin likelihood ratio test; ALMR LR, adjusted Lo-Mendell-Rubin likelihood ratio test; 
BLRT, bootstrap likelihood ratio test.
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TABLE IV
Latent Profile Assignment Probabilities for Each Profile in the Four-Profile LPA Model
Profile 1 Profile 2 Profile 3 Profile 4
Profile 1 (N = 31, 15.5%) 0.92 0.03 0.04 0
Profile 2 (N = 47, 23.5%) 0.02 0.91 0.03 0.04
Profile 3 (N = 32, 16.0%) 0.05 0.03 0.91 0.02
Profile 4 (N = 90, 45.0%) 0 0.02 0.01 0.97
Entropy = 0.88
Latent profile classification is based on the most likely latent class membership. LPA, latent profile analysis.
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TABLE V
Predictors of Latent Profile Membership in the Latent Multinomial Logit Model
Covariate Latent profile
Profile 1 (n = 31) Profile 2 (n = 47) Profile 3 (n = 32) Profile 4
a
 (n = 90)
Odds ratio 95% CI Odds ratio 95% CI Odds ratio 95% CI Odds ratio 95% CI
Sex
    Female — — — — — — — —
    Male 0.9 0.3, 2.2 0.6 0.3, 1.3 0.5 0.2, 1.2 — —
Age 1.1 0.9, 1.3 1.1 0.9, 1.2 0.9 0.8, 1.1 — —
Race/ethnicity
    Non-Hispanic White — — — — — — — —
    Black/African American 0.8 0.2, 2.6 2.0 0.8, 5.1 1.0 0.2, 4.3
    Hispanic 0.8 0.2, 2.7 1.1 0.4, 3.3 2.9 0.9, 9.8
    Other 0.6 0.1, 3.6 1.6 0.4, 6.1 2.9 0.7, 12.2 — —
Other health problems
    No other health problems — — — — — — — —






* 1.3, 9.7 — —
Guardian's highest education 0.7 0.5, 1.03 0.8 0.5, 1.1 1.6 0.99, 2.6 — —
Type of tumor
    Leukemia/lymphoma — — — — — — — —
    Brain tumor 1.0 0.2, 5.8 1.1 0.3, 4.1 2.4 0.6, 9.2
    Solid tumor 2.3 0.8, 6.1 1.5 0.7, 3.6 0.6 0.2, 1.9
Child is in active treatment
    No — — — — — — — —
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